Low Blood Sodium (Hyponatremia)

September 22, 2014

Ultragenyx Pharmaceutical issued
results of a phase I/II extension study of KRN23
(UX023) in adult patients with X-linked hypophosphatemia
(XLH). The extension study
(INT-002) was designed to follow an initial
four-month dose escalation study (INT-001)
that was conducted in the U.S. and Canada. 22
adult patients with XLH were evaluated over
an additional 12 months. Patients received
monthly subcutaneous injections of KRN23
administered at a dose range of 0.1mg/kg to
1mg/kg. Data demonstrated the increases
in serum phosphorus levels, urinary phosphorus
reabsorption and 1,25 dihydroxy
vitamin D levels observed in the initial INT-001
study were generally sustained during the
12-month extension. All patients continued
to demonstrate increases in serum phosphorus
levels. Approximately 52.6%-85.7% of
subjects in the extension study had serum
phosphorus levels that reached the normal
range (2.5mg/dL to 4.5mg/dL) at peak time
on day seven or day 14 after each dose over
this 12-month period. The company plans to
continue development in adult XLH patients
and is enrolling pediatric XLH patients in an
ongoing phase II study.

September 27, 2004

Yamanouchi Pharma America announced data from a clinical study of conivaptan, their vasopressin receptor antagonist for the treatment of dilutional hyponatremia, abnormally low concentrations of serum sodium due to increased body water. The results indicated that conivaptan was able to significantly increase serum sodium levels over the treatment course (the primary endpoint), reach these levels faster, and maintain these increases for a greater period of time (the secondary endpoints), versus placebo. This double-blind, multi-center study enrolled a total of 84 subjects suffering from symptomatic dilutional hyponatremia, including serum sodium levels of 115-130 mEq/L; subjects were treated with placebo or a regimen of 20 mg IV bolus of conivaptan followed by continuous infusion of one of two doses of the drug (40 mg/day or 80 mg/day) for 4 days. An NDA for conivaptan is currently being reviewed for approval by the FDA for the treatment of euvolemic and hypervolemic (dilutional) hyponatremia.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.